Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Bullboard Posts
Comment by TechnicalBuyon Jul 23, 2013 4:01pm
269 Views
Post# 21625496

RE:RE:RE:RE:RE:RE:Medicago bought out for $357m

RE:RE:RE:RE:RE:RE:Medicago bought out for $357mBoy, do I have great news for you then :). The Army program is very much under way. I spoke to the company about this. You can find a reference to it here as well: https://www.kanebiotech.com/pr040313.html (The second wound care product is in collaborative development with the US Army Institute of Surgical Research for combat wound infections).

The clinical trials is also something that the co would like to get under way, but as it costs a significant amount of money they are moving slowly on this issue.

On a separate note, it seems they are far more excited about the potential dental uses of the product as the market opportunity is far greater (think toothpaste, mouth wash and a billion of daily consumers) than any potential drug. The animal program may be a spring to launch them on this path.

Granted this is not a slam dunk by any means, but the potential for this $7m market cap company is tremendous. One of the better biotechs to be invested in in Canada imo.

Regards
TB
[url=https://twitter.com/technicalbuy]follow me on twitter[/url]
Bullboard Posts